Sponsored Lunch Talk | 20 Nov

Title: The Synergistic Effect of D2 and 5-HT7 Antagonism in Managing Schizophrenia and Bipolar I Depression Patients for Functional Recovery

Abstract

This presentation explores the therapeutic potential of LATUDA (Lurasidone), a multi-receptor targeting antipsychotic, in managing schizophrenia and Bipolar I depression, emphasizing functional recovery. The discussion begins with an analysis of Lurasidone’s receptor profile, highlighting its balanced antagonistic action on D2 and 5-HT7 receptors, alongside its partial agonism at 5-HT1A receptors. These unique receptor interactions are shown to contribute to both efficacy and tolerability, providing an improved treatment landscape for patients.

The presentation will elucidate how D2 antagonism, in concert with 5-HT7 antagonism and 5-HT1A agonism, enables Lurasidone to enhance therapeutic outcomes, addressing the positive, negative symptoms and cognitive deficits prevalent in both schizophrenia and Bipolar I depression. The role of these mechanisms in supporting functional and cognitive improvements, crucial for patient quality of life and societal integration, will be examined.

Finally, data on optimal dosing will be reviewed, with clinical insights for tailoring treatment regimens that maximize therapeutic benefit while minimizing side effects. Through these discussions, the speaker will provide a comprehensive overview of Lurasidone’s positioning as an effective and tolerable option for long-term management and functional recovery in schizophrenia and Bipolar I depression.